Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Cybin Inc (NY: CYBN )

10.38 +0.13 (+1.27%)
Official Closing Price Updated: 5:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
38 39 Next >
Cybin Inc. Was Down 70% In 2022 But Has Bounced Back By 59% YTD - Here's Why
A review of Cybin Inc.'s latest quarterly financials, the history of its stock price performance, and the price forecasts for the stock over the next 12 months. 
Via Talk Markets
Cybin: Positive Clinical Trial On Psilocybin Analog For Major Depression & Updates On DMT Analog Program
Psychedelics biotech company Cybin Inc. 
Via Benzinga
Psychedelic Stock Gainers And Losers From March 2, 2023
Via Benzinga
Cybin and The Chopra Foundation to Participate in Featured Session at Upcoming 2023 South by Southwest® Conference
From Cybin Inc.
Via Business Wire
Cybin, GH Research Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From February 28, 2023
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Progress Updates on Two Clinical Development Programs
Via Investor Brand Network
Cybin Announces Positive Data from its CYB003 Phase 1/2a Trial and Provides Update on its CYB004 Development Program
From Cybin Inc.
Via Business Wire
Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More
Two Bills Approved By Hawaii Senators With Governor's Endorsement Hawaii Senate Ways and Means Committee approved a pair of bills aiming to promote and investigate the therapeutic potential of MDMA and... 
Via Benzinga
Psychedelic Stock Gainers And Losers From February 27, 2023
Via Benzinga
"Multi-Bagger" Portfolio Outperforming "Rags-To-Riches" Portfolio By 2-To-1 Margin YTD
Cannabis, psychedelic and plant-based food stocks were extremely oversold in 2022 but perhaps some will bounce back with 
Via Talk Markets
Of The 6 Largest Psychedelic Drug Stocks, Only One Has Not Advanced YTD
The most critical financial information on the health of a company is whether, or not, it has a Net Positive Operating Cash Flow; its Altman -Z Score; its Piotroski F-Score; and the percentage... 
Via Talk Markets
Only 2 Of 5 Cannabis Categories Have Advanced YTD
The 5 categories in the cannabis sector perform quite differently from each other but YTD the common trend is mostly downward. 
Via Talk Markets
Psychedelic Stock Gainers And Losers From February 24, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From February 23, 2023
Via Benzinga
Cybin Stock Down On Laying Off 15% Of Workforce As Part Of A Streamlining Clinical Alignment
Cybin Inc. (NEO:CYBN) (AMEX:CYBN) announced Thursday a streamlining plan aimed at maximizing the company’s operating efficiency and allowing it to focus on critical clinical trials. 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Plan to Streamline Efforts, Maximize Efficiency, Focus on Clinical Trials
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Psychedelic Stock Gainers And Losers From February 22, 2023
Via Benzinga
Cybin Announces Streamlined Clinical Alignment
From Cybin Inc.
Via Business Wire
Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More
Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, New Hampshire's Setback Earlier this week, three bills were introduced and... 
Via Benzinga
Psychedelic Stock Gainers And Losers From February 21, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From February 20, 2023
Via Benzinga
"Multi-Bagger" Portfolio Outperforming "Rags-To-Riches" Portfolio YTD By A 2-To-1 Margin
Cannabis, psychedelic and plant-based food stocks were extremely oversold in 2022. Perhaps some will bounce back with 
Via Talk Markets
6 Largest Psychedelic Stocks Showing Strength; Up 11.5% YTD
A look at the performance of the six largest psychedelic stocks by market capitalization. 
Via Talk Markets
ATAI Life Sciences, GH Research Among Top Psychedelic Movers Of Today
Via Benzinga
Cybin, Compass Pathways Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From February 15, 2023
Via Benzinga
GH Research, Mind Medicine Among Top Psychedelic Movers Of Today
Via Benzinga
Cybin Reports Q3 Earnings, Says Psilocybin Tial Is Progressing As MDD Treatment
Cybin Inc. (NYSE: CYBN) has shared its unaudited financial results for the third quarter that ended Dec. 31, 2022. The company held total cash of $16.9 (CA$22.5) million as of Dec. 31, 2022, and $15... 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Q3 Financial Report, Corporate Highlights
Via Investor Brand Network
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
38 39 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.